284 related articles for article (PubMed ID: 25917991)
1. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts.
Smith LM; Strumpf EC; Kaufman JS; Lofters A; Schwandt M; Lévesque LE
Pediatrics; 2015 May; 135(5):e1131-40. PubMed ID: 25917991
[TBL] [Abstract][Full Text] [Related]
2. Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): A population-based assessment.
Guerra FM; Rosella LC; Dunn S; Wilson SE; Chen C; Deeks SL
Vaccine; 2016 Sep; 34(39):4678-4683. PubMed ID: 27527815
[TBL] [Abstract][Full Text] [Related]
3. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
Nygård S; Nygård M; Orumaa M; Hansen BT
Vaccine; 2023 Aug; 41(37):5469-5476. PubMed ID: 37516572
[TBL] [Abstract][Full Text] [Related]
4. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
Drolet M; Bénard É; Pérez N; Brisson M;
Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
[TBL] [Abstract][Full Text] [Related]
5. Incidence of anogenital warts after the introduction of the quadrivalent HPV vaccine program in Manitoba, Canada.
Righolt CH; Willows K; Kliewer EV; Mahmud SM
PLoS One; 2022; 17(4):e0267646. PubMed ID: 35472093
[TBL] [Abstract][Full Text] [Related]
6. Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study.
Smith LM; Kaufman JS; Strumpf EC; Lévesque LE
CMAJ; 2015 Feb; 187(2):E74-E81. PubMed ID: 25487660
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.
Dominiak-Felden G; Gobbo C; Simondon F
PLoS One; 2015; 10(7):e0132404. PubMed ID: 26147096
[TBL] [Abstract][Full Text] [Related]
8. Early Evidence of the Effectiveness of the Human Papillomavirus Vaccination Program Against Anogenital Warts in Manitoba, Canada: A Registry Cohort Study.
Willows K; Bozat-Emre S; Righolt CH; Kliewer EV; Mahmud SM
Sex Transm Dis; 2018 Apr; 45(4):254-259. PubMed ID: 29465699
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus vaccine efficacy in the prevention of anogenital warts: systematic review and meta-analysis.
Tejada RA; Vargas KG; Benites-Zapata V; Mezones-Holguín E; Bolaños-Díaz R; Hernandez AV
Salud Publica Mex; 2017; 59(1):84-94. PubMed ID: 28423114
[TBL] [Abstract][Full Text] [Related]
10. The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity.
Orumaa M; Kjaer SK; Dehlendorff C; Munk C; Olsen AO; Hansen BT; Campbell S; Nygård M
Vaccine; 2020 Feb; 38(6):1345-1351. PubMed ID: 31917039
[TBL] [Abstract][Full Text] [Related]
11. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
[TBL] [Abstract][Full Text] [Related]
12. The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada.
Steben M; Ouhoummane N; Rodier C; Sinyavskaya L; Brassard P
J Med Virol; 2018 Mar; 90(3):592-598. PubMed ID: 28980715
[TBL] [Abstract][Full Text] [Related]
13. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of school-based and high-risk human papillomavirus vaccination programs against cervical dysplasia in Manitoba, Canada.
Righolt CH; Bozat-Emre S; Mahmud SM
Int J Cancer; 2019 Aug; 145(3):671-677. PubMed ID: 30653261
[TBL] [Abstract][Full Text] [Related]
15. A Review of the Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: 10 Years of Clinical Experience in Canada.
Steben M; Tan Thompson M; Rodier C; Mallette N; Racovitan V; DeAngelis F; Stutz M; Rampakakis E
J Obstet Gynaecol Can; 2018 Dec; 40(12):1635-1645. PubMed ID: 30341021
[TBL] [Abstract][Full Text] [Related]
16. Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2013 Aug; 31(37):3899-905. PubMed ID: 23820080
[TBL] [Abstract][Full Text] [Related]
17. The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts.
Clark M; Jembere N; Kupets R
Prev Med; 2021 Sep; 150():106641. PubMed ID: 34048822
[TBL] [Abstract][Full Text] [Related]
18. Impact of a single-age cohort human papillomavirus vaccination strategy in Catalonia, Spain: Population-based analysis of anogenital warts in men and women.
Brotons M; Monfil L; Roura E; Duarte-Salles T; Casabona J; Urbiztondo L; Cabezas C; Bosch FX; de Sanjosé S; Bruni L
Prev Med; 2020 Sep; 138():106166. PubMed ID: 32565118
[TBL] [Abstract][Full Text] [Related]
19. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
20. Impact of HPV vaccination on anogenital warts and respiratory papillomatosis.
Wangu Z; Hsu KK
Hum Vaccin Immunother; 2016 Jun; 12(6):1357-62. PubMed ID: 27217191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
